eligibility_summary
Adults 18–75 with BCMA+ measurable multiple myeloma, ECOG ≤2, life expectancy ≥12 wks, adequate marrow, renal (CrCl ≥30), hepatic (AST/ALT ≤2.5×ULN, bili ≤1.5×ULN), pancreatic enzymes ≤2×ULN, O2 sat >92%, prior ≥3 MoAs and relapsed/refractory/intolerant. Exclude asymptomatic/EM-only MM, PCL, amyloidosis, CNS disease, pregnancy, active infection/viral positivity, major cardiac/pulmonary disease, recent MI/ASCT, prior allo-HSCT, recent investigational therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Autologous, triple‑target CAR-T cell therapy against CD19, CD22, and BCMA (arm text lists CD19/CD20/BCMA). Type: cellular gene therapy/immunotherapy using patient T cells engineered with chimeric antigen receptors. Mechanism: CARs bind target antigens, triggering T-cell activation (via CD3ζ/costim domains), proliferation, cytokine release, and cytolytic killing of malignant cells. Preconditioning: cyclophosphamide (alkylating agent) + fludarabine (purine analog) for lymphodepletion to enhance CAR-T expansion. Targets/pathways: BCMA on malignant plasma cells (B-cell maturation/survival axis), CD19 and CD22 on B-lineage cells, multi-antigen targeting aims to limit antigen escape and eradicate myeloma and precursor B cells.